Skip to product information
1 of 4

Prime Peptides

Tirzepatide

Tirzepatide

Regular price $130.00
Regular price Sale price $130.00
Sale Sold out
Shipping calculated at checkout.
Size
  • Significant Weight Loss
  • Improves Glycemic Control
  • Cardiovascular Benefits

Tirzepatide is a novel dual GIP and GLP-1 receptor agonist known for its potent effects on weight loss, glycemic control, and potential cardiovascular benefits. It is primarily used in the treatment of type 2 diabetes and obesity, helping to manage these conditions effectively while improving overall metabolic health.

Legal Notice: This item is available exclusively for scientific research purposes. It is sold in a lyophilized (freeze-dried) state, contained within a hermetically sealed and sterile vial. Use requires extra equipment such as bacteriostatic water for reconstitution, syringes and needles for extraction, and alcohol swabs to sanitize vial caps. The cap color, may differ from the images shown.

Benefits and Applications

  • Significant Weight Loss: Tirzepatide has demonstrated remarkable efficacy in promoting weight loss in individuals with type 2 diabetes and obesity. Clinical trials have shown greater weight reduction compared to placebo and other antidiabetic medications, making it a promising option for weight management.
  • Improves Glycemic Control: Tirzepatide helps improve glycemic control by increasing insulin secretion, reducing glucagon secretion, and slowing gastric emptying. It lowers fasting and postprandial glucose levels, improves HbA1c levels, and reduces the risk of hypoglycemia in individuals with type 2 diabetes.
  • Cardiovascular Benefits: Tirzepatide has shown cardiovascular benefits beyond glycemic control, including reductions in the risk of major adverse cardiovascular events (MACE) such as heart attack, stroke, and cardiovascular death. It helps improve vascular function, reduce inflammation, and lower blood pressure, leading to improved cardiovascular outcomes.
  • Potential for Non-Diabetic Conditions: Tirzepatide may have potential applications beyond type 2 diabetes, including obesity, non-alcoholic fatty liver disease (NAFLD), and chronic kidney disease (CKD). It shows promise in improving metabolic health and reducing the risk of related complications in these conditions.
  • Convenience of Administration: Tirzepatide is administered once weekly via subcutaneous injection, offering convenience and adherence benefits compared to other antidiabetic medications that require more frequent dosing.

Research and Studies

Study Title: "Efficacy of Tirzepatide in Type 2 Diabetes Management"

  • Method: This pivotal phase 3 clinical trial assessed the effectiveness of tirzepatide in improving glycemic control in patients with type 2 diabetes. Participants were randomized to receive either tirzepatide at varying doses or a comparator medication.
  • Results: Tirzepatide significantly lowered HbA1c levels, with reductions up to 2.4% from baseline, surpassing the reductions seen with the comparator medications.
  • Conclusion: Tirzepatide is highly effective in controlling blood glucose levels in patients with type 2 diabetes, offering a substantial improvement over existing therapies.

Study Title: "Impact of Tirzepatide on Weight Loss in Patients with Obesity"

  • Method: A randomized controlled trial investigated the weight loss effects of tirzepatide in patients with obesity, without diabetes.
  • Results: Participants receiving tirzepatide achieved a significant reduction in body weight, with an average weight loss of approximately 15% of their initial body weight over the study period.
  • Conclusion: Tirzepatide not only improves glycemic control but also significantly reduces body weight, making it a potent therapeutic option for obesity management.

Study Title: "Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes"

  • Method: This study evaluated the cardiovascular safety and benefits of tirzepatide in patients with type 2 diabetes at high risk of cardiovascular events.
  • Results: Tirzepatide demonstrated a reduction in major adverse cardiovascular events compared to placebo, indicating a potential cardioprotective effect.
  • Conclusion: Besides its metabolic benefits, tirzepatide may offer cardiovascular advantages for patients with type 2 diabetes, contributing to a broader impact on health beyond glycemic control.

Study Title: "Tirzepatide and Its Role in Beta-Cell Function and Insulin Sensitivity"

  • Method: This mechanistic study explored how tirzepatide affects beta-cell function and insulin sensitivity in type 2 diabetes patients.
  • Results: Tirzepatide improved beta-cell responsiveness and enhanced insulin sensitivity more effectively than other treatments.
  • Conclusion: The dual action of tirzepatide on both GIP and GLP-1 receptors contributes to its effectiveness, enhancing both beta-cell function and insulin sensitivity, which are critical in the pathophysiology of type 2 diabetes.

These studies underscore the potential of tirzepatide as a transformative treatment for type 2 diabetes and obesity, with additional benefits in cardiovascular health and metabolic function. Its dual-action mechanism provides a powerful tool against these chronic conditions, reflecting significant advancements in the pharmacological management of metabolic diseases.

Mechanism of Action

Tirzepatide works through a unique mechanism involving the stimulation of two key hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. These receptors play crucial roles in metabolic regulation, particularly in the control of blood glucose levels. Here’s how tirzepatide acts through each receptor:

  1. GLP-1 Receptor Agonism:
  2. GIP Receptor Agonism:

The combined action on these two receptors makes tirzepatide particularly effective, not only in lowering blood glucose levels but also in promoting significant weight loss. This dual mechanism is relatively novel in the treatment of type 2 diabetes and represents a significant advance over medications that target only the GLP-1 receptor. By harnessing both pathways, tirzepatide offers a more comprehensive approach to managing diabetes, addressing both core aspects of the disease and its common comorbid condition, obesity.

Safety and Side Effects

Side Effects:
Tirzepatide has several potential side effects, which include:

  • Gastrointestinal issues: Commonly reported side effects include nausea, vomiting, diarrhea, decreased appetite, and constipation. These symptoms are typical of medications that affect GLP-1 receptors and are often most pronounced when treatment is initiated.
  • Hypoglycemia: Especially when used in combination with other diabetes medications, such as insulin or sulfonylureas, tirzepatide can increase the risk of low blood sugar.
  • Injection site reactions: Such as redness, swelling, or irritation, since tirzepatide is administered via injection.

Safety Profile:

  • FDA approval: Tirzepatide was approved by the FDA for the treatment of type 2 diabetes, reflecting positive outcomes from extensive clinical trials regarding its safety and efficacy.
  • Weight management benefits: In addition to improving glycemic control, tirzepatide has shown significant benefits in weight loss, which can be particularly advantageous for diabetic patients struggling with obesity.
  • Long-term effects: Although the long-term effects are still under study, initial clinical trials have been promising, showing significant improvements in HbA1c levels and weight, with a safety profile consistent with other drugs in its class.

FAQs

  • Satisfaction Guaranteed
  • 3rd Party Tested
  • Fast Shipping
View full details